CL2021000146A1 - Anticuerpos humanizados contra psma - Google Patents

Anticuerpos humanizados contra psma

Info

Publication number
CL2021000146A1
CL2021000146A1 CL2021000146A CL2021000146A CL2021000146A1 CL 2021000146 A1 CL2021000146 A1 CL 2021000146A1 CL 2021000146 A CL2021000146 A CL 2021000146A CL 2021000146 A CL2021000146 A CL 2021000146A CL 2021000146 A1 CL2021000146 A1 CL 2021000146A1
Authority
CL
Chile
Prior art keywords
antibodies against
humanized antibodies
against psma
psma
antibody
Prior art date
Application number
CL2021000146A
Other languages
English (en)
Inventor
Torsten Hechler
Andreas Pahl
Original Assignee
Heidelberg Pharma Res Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heidelberg Pharma Res Gmbh filed Critical Heidelberg Pharma Res Gmbh
Publication of CL2021000146A1 publication Critical patent/CL2021000146A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cell Biology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente solicitud se refiere a anticuerpos humanizados y/o desinmunizados, fragmentos de anticuerpos o derivados de anticuerpos que se unen al antígeno de membrana específico de la próstata (PSMA) y métodos para usar dichos anticuerpos, fragmentos de anticuerpos o derivados de anticuerpos en el tratamiento del cáncer de próstata y otras enfermedades neoplásicas y neurológicas.
CL2021000146A 2018-07-31 2021-01-18 Anticuerpos humanizados contra psma CL2021000146A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18186591 2018-07-31

Publications (1)

Publication Number Publication Date
CL2021000146A1 true CL2021000146A1 (es) 2021-07-30

Family

ID=63259376

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021000146A CL2021000146A1 (es) 2018-07-31 2021-01-18 Anticuerpos humanizados contra psma

Country Status (26)

Country Link
US (1) US11976131B2 (es)
EP (1) EP3830132B1 (es)
JP (1) JP7586399B2 (es)
KR (1) KR102927925B1 (es)
CN (1) CN112533956B (es)
AR (1) AR115288A1 (es)
AU (1) AU2019312801B2 (es)
BR (1) BR112021001237A2 (es)
CA (1) CA3104800A1 (es)
CL (1) CL2021000146A1 (es)
CO (1) CO2021000386A2 (es)
DK (1) DK3830132T5 (es)
ES (1) ES2934963T3 (es)
FI (1) FI3830132T3 (es)
HR (1) HRP20230115T1 (es)
HU (1) HUE061078T2 (es)
IL (1) IL279823B2 (es)
LT (1) LT3830132T (es)
MX (1) MX2021000783A (es)
PL (1) PL3830132T3 (es)
PT (1) PT3830132T (es)
RS (1) RS63943B1 (es)
SG (1) SG11202100607RA (es)
SI (1) SI3830132T1 (es)
WO (1) WO2020025564A1 (es)
ZA (1) ZA202008095B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016089862A1 (en) * 2014-12-01 2016-06-09 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same
SG11202110287QA (en) 2019-04-24 2021-10-28 Heidelberg Pharma Res Gmbh Amatoxin antibody-drug conjugates and uses thereof
CA3195572A1 (en) 2020-11-04 2022-05-12 Heidelberg Pharma Research Gmbh Composition comprising a combination of immune checkpoint inhibitor and antibody-amatoxin conjugate for use in cancer therapy
MX2024002476A (es) * 2021-08-27 2024-05-20 Janssen Biotech Inc Anticuerpos anti-psma y usos de estos.
AU2023251200A1 (en) 2022-04-07 2024-10-03 Heidelberg Pharma Research Gmbh Methods of improving the therapeutic index of amatoxin-antibody conjugates
KR20250158048A (ko) 2023-03-03 2025-11-05 아스널 바이오사이언시스, 인크. Psma 및 ca9을 표적으로 하는 시스템
CN120936385A (zh) 2023-03-13 2025-11-11 海德堡医药研究有限责任公司 用于在癌症治疗中使用的皮下施用的抗体-药物缀合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1997035616A1 (en) 1996-03-25 1997-10-02 Pacific Northwest Cancer Foundation Monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
CA2380783C (en) 1999-07-29 2009-01-27 Yashwant Deo Human monoclonal antibodies to prostate specific membrane antigen
US7666414B2 (en) * 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
US7462697B2 (en) * 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
EP1726650A1 (en) * 2005-05-27 2006-11-29 Universitätsklinikum Freiburg Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
DE202007018529U1 (de) 2007-07-07 2008-12-04 Chamalow S.A. Implantierbarer Funkfrequenzdefibrillator R.F.
JP6126782B2 (ja) * 2008-10-01 2017-05-10 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー 異種間特異的ｐｓｍａ×ｃｄ３二重特異性単鎖抗体
JP2012505654A (ja) * 2008-10-14 2012-03-08 ヤンセン バイオテツク，インコーポレーテツド 抗体をヒト化及び親和性成熟する方法
TWI653333B (zh) 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
EP3587454A1 (en) * 2018-06-27 2020-01-01 Albert-Ludwigs-Universität Freiburg Chimeric antigen receptors that bind to prostate specific membrane antigen

Also Published As

Publication number Publication date
CO2021000386A2 (es) 2021-07-19
BR112021001237A2 (pt) 2021-04-27
CA3104800A1 (en) 2020-02-06
JP7586399B2 (ja) 2024-11-19
IL279823B2 (en) 2026-02-01
EP3830132A1 (en) 2021-06-09
FI3830132T3 (fi) 2023-01-13
IL279823B1 (en) 2025-10-01
CN112533956A (zh) 2021-03-19
SG11202100607RA (en) 2021-02-25
CN112533956B (zh) 2025-05-06
PL3830132T3 (pl) 2023-04-17
SI3830132T1 (sl) 2023-03-31
US20230250189A1 (en) 2023-08-10
LT3830132T (lt) 2023-02-10
DK3830132T3 (da) 2023-01-02
MX2021000783A (es) 2021-03-31
DK3830132T5 (da) 2024-08-19
PT3830132T (pt) 2023-01-05
HRP20230115T1 (hr) 2023-06-09
AR115288A1 (es) 2020-12-16
KR20210039389A (ko) 2021-04-09
KR102927925B1 (ko) 2026-02-13
AU2019312801A1 (en) 2021-03-11
JP2021532778A (ja) 2021-12-02
ES2934963T3 (es) 2023-02-28
RS63943B1 (sr) 2023-02-28
WO2020025564A1 (en) 2020-02-06
AU2019312801B2 (en) 2025-09-11
HUE061078T2 (hu) 2023-05-28
ZA202008095B (en) 2023-09-27
EP3830132B1 (en) 2022-11-23
IL279823A (en) 2021-03-01
US11976131B2 (en) 2024-05-07

Similar Documents

Publication Publication Date Title
CO2021000386A2 (es) Anticuerpos humanizados contra psma
CL2023000907A1 (es) Anticuerpos de unión a gprc5d
AR119295A1 (es) Moléculas de unión a antígeno ligantes de cea
MX2021004808A (es) Anticuerpos contra la epcam, anticuerpos activables e inmunoconjugados y usos de estos.
ECSP19078429A (es) Anticuerpos anti-trem2 y métodos para utilizarlos
CL2020002446A1 (es) Anticuerpos contra mica y/o micb y sus usos
CO2021009693A2 (es) Proteínas de unión a antígeno del receptor gamma anti-il2
AR107442A1 (es) Anticuerpos contra el receptor huérfano similar al receptor tirosina quinasa 1 (anti-ror1), anticuerpos biespecíficos que se unen a ror1 y al antígeno cd3, y métodos para el tratamiento del cáncer
CR20190346A (es) Conjugados de fármacos y anticuerpos anti-ccr7
CR20170096A (es) Tratamientos conjuntos con anticuerpos anti cd40
MX2017012802A (es) Anticuerpos antisortilina y métodos para su uso.
PE20190737A1 (es) Anticuerpos anti-cd27
CL2025000403A1 (es) Anticuerpo anti-lilrb1 y usos del mismo
CL2019002735A1 (es) Anticuerpos que se unen a steap-1.
AR117735A1 (es) ANTICUERPOS MONOCLONALES QUE SE UNEN ESPECÍFICAMENTE A LA REGIÓN b DE LA FAMILIA TRBV-9 DEL RECEPTOR DE CÉLULAS T HUMANO, Y LOS MÉTODOS PARA SU USO
BR112016024214A2 (pt) anticorpos antigênicos anti-tf humanizados
CO2023002375A2 (es) Anticuerpos contra ilt2 y uso de los mismos
AR114129A1 (es) ANTICUERPOS TERAPÉUTICOS DIRIGIDOS CONTRA sPLA2-GIB Y SUS USOS
AR081321A1 (es) N-cadherina: un blanco para el diagnostico y la terapia del cancer
CO2026002111A2 (es) Anticuerpos gucy2c y usos de estos
AR113343A1 (es) ANTICUERPO MONOCLONAL ANTI-IL-5Ra
MX2020011385A (es) Anticuerpos terapeuticos que se unen antigenos de lewis b y lewis y biantenarios.
MX2021001604A (es) Tratamiento del cáncer con un anticuerpo.
CL2025002685A1 (es) Anticuerpos multiespecíficos anti-cldn6 y anti-cd3 y métodos de uso.
MX2025010218A (es) Anticuerpos multiespecificos anti-cldn6 y anti-cd3 y metodos de uso